Suppression of testosterone secretion in dogs by a long-acting formulation of the LHRH agonist buserelin

Sandow, J.; Seidel, H.; Rechenberg, W. von; Brunk, R

doi:10.1530/acta.0.111s077

Acta Endocrinologica

1986

DOI: 10.1530/acta.0.111s077

|View full text |Cite

Suppression of testosterone secretion in dogs by a long-acting formulation of the LHRH agonist buserelin

J. Sandow¹,

H. Seidel²,

W. von Rechenberg³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1989

1996

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, these slow release formulations have been based upon incorporation of GnRH agonist in a matrix of polylactide/glycolide copolymers (PLG) and administered as a small rod or as microcapsules (6,(11)(12)(13)(14)(15). The matrix material must sat¬ isfy a number of criteria; be non-irritant, non-toxic and non-carcinogenic and allow release of the pep¬ tide at a controlled optimal rate.…”

mentioning

confidence: 99%

Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant: reversible suppression of the menstrual cycle in the macaque

Fraser

Sandow²,

Seidel³

et al. 1989

Acta Endocrinologica

Self Cite

View full text Add to dashboard Cite

The use of polyhydroxybutyric acid as a matrix for delivery of the GnRH agonist buserelin was studied in adult stumptailed macaques with regular menstrual cycles. This material contained 5.0 mg buserelin in a disk of 0.6 cm diameter and 0.15 cm thickness. The effects on pituitary-ovarian function were examined and buserelin release profiles from 30 000 and 150 000 molecular weight polyhydroxybutyric acid matrices were compared. In an attempt to reduce the high initial release rate of buserelin from these disks, and to prolong the effective period of release, implants of 30 000 molecular weight were coated with cyanoacrylate. The implants were removed after 28, 35 or 42 days for the 30 000, the 150 000 and the coated implants, respectively. The urinary excretion profile for the agonist revealed a high initial release of buserelin from these implants followed by a rapid decline. The coated disks released significantly less (p < 0.05) buserelin over the first 3 days than did either of the uncoated implants, but maintained release of the agonist over a longer period. Inhibition of ovulation and suppression of estradiol secretion lasted for the duration of treatment in 3 of 5 macaques receiving the 30 000 implant, and in 5 of 5 receiving the 150 000 or the coated implant. In 3 macaques in whom the coated implant was left in situ, ovulation was suppressed for 104 \ m=+-\ 3.7 days. These results demonstrate that a polyhydroxybutyric acid matrix can be used as a depot formulation for a GnRH agonist and that improved control of release of the agonist can be achieved by coating such implants with cyanoacrylate. This approach may be useful in experimental and clinical situations and may be applicable for delivery of other peptide hormones.The ability of agonist analogues of gonadotropinreleasing hormone to suppress pituitary-ovarian function by inducing desensitization of the pitui¬ tary gonadotrope has been studied extensively for evaluation as a potential contraceptive and in treatment of sex hormone-dependent disorders (reviewed in 1). These therapeutic advances have been made despite the fact that GnRH analogues cannot be administered by mouth as they are inac¬ tivated when taken orally. Studies using daily in¬ jections were followed by the development of nasal sprays for clinical application (2,3). Although nasal administration has the advantage of long-term self-medication, it has a low efficiency of absorp¬ tion and there are variations in the dose require¬ ments for ovarian suppression between individ¬ uals. Furthermore, multiple daily injections or nasal spray administration are generally unsuit¬ able for application to animal studies. Administra¬ tion of GnRH and its agonists by long-term infu¬ sion shows that continued exposure is most effec¬ tive in suppressing pituitary-gonadal function; pi¬ tuitary receptors and gonadotropin content in ex¬ perimental animals are more suppressed than after daily injections (4)(5)(6)(7)(8).Initially, such experiments involved infusion of peptide via osmotic minipumps or portable...

show abstract

mentioning

confidence: 99%

Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant: reversible suppression of the menstrual cycle in the macaque

Fraser

Sandow²,

Seidel³

et al. 1989

Acta Endocrinologica

Self Cite

View full text Add to dashboard Cite

show abstract

Biosynthetic polyhydroxyalkanoates and their potential in drug delivery

Pouton

Akhtar

1996

Advanced Drug Delivery Reviews

335

135

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Suppression of testosterone secretion in dogs by a long-acting formulation of the LHRH agonist buserelin

Cited by 2 publications

References 0 publications

Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant: reversible suppression of the menstrual cycle in the macaque

Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant: reversible suppression of the menstrual cycle in the macaque

Biosynthetic polyhydroxyalkanoates and their potential in drug delivery

Contact Info

Product

Resources

About